GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinopharm Group Co Ltd (HKSE:01099) » Definitions » 3-Year FCF Growth Rate

Sinopharm Group Co (HKSE:01099) 3-Year FCF Growth Rate : 3.00% (As of Sep. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Sinopharm Group Co 3-Year FCF Growth Rate?

Sinopharm Group Co's Free Cash Flow per Share for the three months ended in Sep. 2023 was HK$0.00.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 3.00% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 98.20% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 8.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Sinopharm Group Co was 208.00% per year. The lowest was -73.80% per year. And the median was 22.00% per year.


Competitive Comparison of Sinopharm Group Co's 3-Year FCF Growth Rate

For the Medical Distribution subindustry, Sinopharm Group Co's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sinopharm Group Co's 3-Year FCF Growth Rate Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Sinopharm Group Co's 3-Year FCF Growth Rate falls into.



Sinopharm Group Co 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Sinopharm Group Co  (HKSE:01099) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Sinopharm Group Co 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Sinopharm Group Co's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinopharm Group Co (HKSE:01099) Business Description

Traded in Other Exchanges
Address
No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023
Sinopharm Group was founded in 2003 and listed on the Hong Kong Stock Exchange in September 2009. Its main business is drug distribution in mainland China, which contributes about 75% of total revenue. It is the largest drug distributor, with approximately 20% market share. Other notable segments are medical device distribution, which contributes about 20% of revenue, and retail pharmacies, which contributes about 5%. These are fast-growing industries, where government policy is designed to encourage consolidation and promote large players with scale and efficiency advantages.

Sinopharm Group Co (HKSE:01099) Headlines

No Headlines